Výsledky vyhledávání - "Ashley Crouch"

Multi-center retrospective study evaluating the efficacy and safety of apixaban versus warfarin for treatment of venous thromboembolism in patients with severe obesity

Autor: Ashley, Crouch, Tsz Hin, Ng, Denise, Kelley, Tamara, Knight, Stephanie, Edwin, Ina, Yun

Publikováno v: PharmacotherapyREFERENCES. 42(2)

Direct oral anticoagulants are the standard of care for venous thromboembolism (VTE) treatment. These agents are recommended regardless of patient weight and body mass index (BMI). However, there remains limited evidence supporting the use of apixaba

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ee20aa69b84c4b080de2c129bb565c7
https://pubmed.ncbi.nlm.nih.gov/34904263

Zobrazit plný text záznamu

Evaluation of low dose famciclovir as herpes simplex virus and varicella zoster virus prophylaxis in cytomegalovirus low‐risk solid organ transplant recipients

Autor: Camille N. Kotton, Christin C. Rogers, Mariesa Le, Sarah Shao, Ashley Crouch

Publikováno v: Transplant Infectious Disease. 23

Objective Famciclovir is a recommended option for herpes simplex virus (HSV) and varicella-zoster virus (VZV) prophylaxis in cytomegalovirus (CMV) low-risk solid organ transplant (SOT) recipients in current guidelines; however there is currently no d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74e07877e46a0b01c555a506f977ac95
https://doi.org/10.1111/tid.13711

Zobrazit plný text záznamu

ALL-318: Real-World Outcomes of Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Who Did Not Receive Allogeneic Stem Cell Transplant at the University of Michigan

Autor: Ashley Crouch, Lydia Benitez-Colon, Charles E. Foucar, Patrick W. Burke, Bernard L. Marini, Dale L. Bixby, Radhika Takiar, Anthony J. Perissinotti

Publikováno v: Clinical Lymphoma Myeloma and Leukemia. 21:S275

Context: The current standard of care for Ph+ ALL is concurrent chemotherapy or corticosteroids with a TKI, followed by an allogeneic transplant for those who are eligible and have attained complete morphologic remission. However, recent studies have

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e5e739d4e815e5fb77127f31a07e371c
https://doi.org/10.1016/s2152-2650(21)01663-3

Zobrazit plný text záznamu

Lenalidomide Plus Hypomethylating Agent as a Treatment Option in Acute Myeloid Leukemia With Recurrent Genetic Abnormalities-AML With inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM

Autor: Patrick W. Burke, Ashley Crouch, Bernard L. Marini, Harry P. Erba, Anthony J. Perissinotti, Lauren E. Merz, Dale L. Bixby

Publikováno v: Clinical lymphoma, myelomaleukemia. 20(1)

Introduction Acute myeloid leukemia (AML) is a heterogeneous clonal hematopoietic neoplasm. The cytogenetic changes associated with AML affect the response rate and survival and are one of the most important independent prognostic factors. AML with i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d1ab0fb4e0fdffb6be9de9718c0e1df
https://pubmed.ncbi.nlm.nih.gov/31711889

Zobrazit plný text záznamu

Intrathecal alemtuzumab: a potential treatment of refractory leptomeningeal T-cell prolymphocytic leukemia

Autor: Dale L. Bixby, Lydia L. Benitez, Heather Fox, Patrick W. Burke, Sarah Choi, Amy Skyles, Bernard L. Marini, Ashley Crouch, Fares Alsawah, Anthony J. Perissinotti, Kristen Pettit

Publikováno v: Blood advances. 3(21)

Key Points This is the first report of successful treatment of therapy-resistant leptomeningeal T-PLL with intrathecal alemtuzumab. Intrathecal alemtuzumab is a potentially safe and efficacious therapeutic alternative for treatment of leptomeningeal

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b1fdff769652eef09d7d173928cdde3
https://pubmed.ncbi.nlm.nih.gov/31698446

Zobrazit plný text záznamu

The FOSSIL Study: FLAG or standard 7+3 induction therapy in secondary acute myeloid leukemia

Autor: Moshe Talpaz, James R. Uebel, Patrick W. Burke, Ashley Crouch, Gianni B. Scappaticci, Ivan Maillard, Anthony J. Perissinotti, Dale L. Bixby, Victoria R Nachar, Bernard L. Marini, Vera Vulaj

Publikováno v: Leukemia research. 70

Patients with secondary acute myeloid leukemia (sAML) have poor outcomes, with CR/CRi rates of 25-35% with standard 7 + 3 induction chemotherapy, while single center non-comparative analyses suggest promising outcomes with FLAG. We conducted a single

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::082d938e030222eb17d9b71fe8b08946
https://pubmed.ncbi.nlm.nih.gov/29908418

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání